Bioatla Intrinsic Stock Value – BioAtla Receives Positive Analysts’ Ratings for its Clinical-Stage Cancer Therapeutics
May 26, 2023
Trending News 🌧️
BIOATLA ($NASDAQ:BCAB): On May 23, 2023, Bloomberg.com reported that analysts have given BioAtla, Inc. a Moderate Buy consensus rating. BioAtla is a biopharmaceutical company specializing in clinical-stage cancer therapeutics based on antibody technology. The company is led by an experienced management team with extensive experience in the biotechnology industry. BioAtla’s current pipeline includes five clinical-stage cancer drugs designed to work together to attack and kill cancer cells. The products are designed to target key areas of a tumor in order to disrupt its growth and promote tumor regression.
The company also has two preclinical programs targeting novel cancer pathways to further enhance its portfolio. The analysts’ ratings reflect the company’s promising future prospects as a leader in the field of clinical-stage cancer therapeutics. With their innovative approach to cancer treatment, BioAtla is well-positioned to capitalize on the growing demand for new cancer treatments. As such, the analysts’ ratings signal that the company’s stock is likely to continue performing favorably in the near future.
Share Price
On Thursday, analysts rated BioAtla Inc. positively for its clinical-stage cancer therapeutics. This is great news for the company, as its stock opened at $3.2 and closed at $3.0, a 7.1% drop from its prior closing price of $3.2. Investors now have higher hopes that the company will be able to make progress in producing effective treatments for deadly cancers. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bioatla. BioAtla_Receives_Positive_Analysts_Ratings_for_its_Clinical-Stage_Cancer_Therapeutics”>More…
| Total Revenues | Net Income | Net Margin |
| 0 | -109.69 | -38436.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bioatla. BioAtla_Receives_Positive_Analysts_Ratings_for_its_Clinical-Stage_Cancer_Therapeutics”>More…
| Operations | Investing | Financing |
| -87.94 | -0.3 | 61.5 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bioatla. BioAtla_Receives_Positive_Analysts_Ratings_for_its_Clinical-Stage_Cancer_Therapeutics”>More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 204.55 | 48.12 | 3.28 |
Key Ratios Snapshot
Some of the financial key ratios for Bioatla are shown below. BioAtla_Receives_Positive_Analysts_Ratings_for_its_Clinical-Stage_Cancer_Therapeutics”>More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -71.3% | – | -38159.6% |
| FCF Margin | ROE | ROA |
| -25255.2% | -41.2% | -33.9% |
Analysis – Bioatla Intrinsic Stock Value
GoodWhale has conducted an analysis of BIOATLA’s financials and our proprietary Valuation Line has calculated the fair value of BIOATLA’s share to be around $11.9. Currently, BIOATLA’s stock is trading at $3.0, which means it is undervalued by 74.7%. We believe this presents an attractive investment opportunity for potential investors. BioAtla_Receives_Positive_Analysts_Ratings_for_its_Clinical-Stage_Cancer_Therapeutics”>More…
Peers
The biotech industry is competitive, and nowhere is this more apparent than in the cancer immunotherapy field. BioAtla Inc is a leading company in this field, but it faces stiff competition from Y-mAbs Therapeutics Inc, Orphazyme AS, and Axsome Therapeutics Inc. All four companies are working to develop innovative treatments that can harness the power of the immune system to fight cancer. While BioAtla may be the current leader in the field, its competitors are quickly catching up, and it remains to be seen who will emerge victorious in this race to develop lifesaving treatments.
– Y-mAbs Therapeutics Inc ($NASDAQ:YMAB)
Agriculture and Biotechnology
Aimmune Therapeutics, Inc. is a biopharmaceutical company, which focuses on developing treatments for potentially life-threatening food allergies. Its product candidates include AR101 for peanut allergy, and AR201 for egg allergy. The company was founded by Stephen D. Miller, Mark J. Corrigan, and Ronald J. Stoddard on February 3, 2011 and is headquartered in Brisbane, CA.
– Orphazyme AS ($OTCPK:OZYMF)
Orphazyme AS is a pharmaceutical company that focuses on the development of treatments for rare diseases. The company has a market cap of 5.86M as of 2022 and a Return on Equity of -845.21%. The company’s focus on rare diseases makes it a unique player in the pharmaceutical industry, and its strong financial position gives it the ability to invest in the research and development needed to bring new treatments to market. However, the company’s high debt levels could be a concern if interest rates rise or if the company is unable to generate enough revenue to cover its interest payments.
– Axsome Therapeutics Inc ($NASDAQ:AXSM)
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders. The company’s lead product candidate, AXS-05, is in development for the treatment of major depressive disorder (MDD), Alzheimer’s disease (AD), and migraine. The company’s other product candidates include AXS-12 for the treatment of Parkinson’s disease and AXS-07 for the treatment of chronic pain and other indications.
As of 2022, Axsome Therapeutics Inc had a market cap of 2.05B and a Return on Equity of -599.9%. The company’s lead product candidate, AXS-05, was in development for the treatment of major depressive disorder (MDD), Alzheimer’s disease (AD), and migraine. The company’s other product candidates included AXS-12 for the treatment of Parkinson’s disease and AXS-07 for the treatment of chronic pain and other indications.
Summary
Analysts have given BioAtla, Inc. a consensus rating of “Moderate Buy” for its clinical-stage cancer therapeutics. On May 23, 2023, the stock price of the company dropped despite the positive consensus given. Investing analysis suggests that investors may be apprehensive to invest in a clinical-stage biopharmaceutical company due to its high risk and potential low returns. However, with the positive consensus given by analysts, investors should consider the long-term potential of the company and its potential to generate returns if it successfully develops and commercializes its products.
Related Posts
Recent Posts
